The Cenobamate Monotherapy study is a clinical trial for adults with either newly
diagnosed or recurrent partial-onset epilepsy who have had minimal to no exposure to
other anti-seizure medications recently. The efficacy (effectiveness) of cenobamate as
adjunctive (add on, combination) therapy for drug resistant partial-onset epilepsy has
been studied. Although approved for monotherapy in the US, there is little formal data
regarding the effectiveness and side effect profile of cenobamate monotherapy.
Patient eligibility for the Cenobamate Monotherapy study will be assessed by study staff
based on study criteria which includes:
– Patients with newly diagnosed or recurrent partial-onset epilepsy
– Patients between 18-74 years of age (inclusive)
– Patients who have minimal to no exposure to other anti-seizure medications in
the recent past
For more information about the Cenobamate study, and to see if you may qualify,
please email ResearchNCNE@neurocenterne.com / call 781-551-5812 opt.2.